Introduction {#sec1_1}
============

Diabetic neuropathy is a long-term complication of diabetes that can cause considerable morbidity in many patients, leading to a deterioration of their quality of life. Previously reported pathways relevant for the development of diabetic neuropathy include the glucose flux/polyol pathway (aldolase reductase, sorbitol), the hexosamine pathway (fructose-6P), the accumulation of advanced glycation end-products and several other mechanisms \[[@B1]\]. A deficiency of vitamin D \[25-hydroxyvitamin D, 25(OH)D\] is common in patients with diabetes, and low concentrations are associated with the presence and the severity of sensory neuropathy in diabetes \[[@B2],[@B3]\]. The mechanisms and pathophysiology of neuropathy are associated with hyperglycemia via microvascular injury or direct neuronal metabolic injury \[[@B2]\]. Vitamin D deficiency has been shown to be an independent risk factor for diabetic peripheral neuropathy (DPN) \[[@B3],[@B4]\]. Topical and oral vitamin D have been reported to significantly reduce the symptoms and pain of DPN \[[@B5],[@B6],[@B7]\]. However, no case-control clinical trials have been reported that demonstrate the efficacy of vitamin D supplementation on the symptoms of DPN. We hypothesized that correction of a vitamin D deficiency may directly or indirectly improve the symptoms of DPN. This study evaluated the potential efficacy of short-term oral vitamin D supplementation on neuropathy in patients with type 2 diabetes mellitus, making use of validated neuropathy assessment tools: a neuropathy symptom score (NSS), a neuropathy disability score (NDS) and electrophysiological studies, i.e. a nerve conduction study (NCS).

Materials and Methods {#sec1_2}
=====================

Study Design {#sec2_1}
------------

This study involved an interventional, prospective, nonrandomized, double-blind, placebo-controlled clinical trial lasting 8 weeks. It assessed, by means of an NSS, an NDS and an NCS, the efficacy of vitamin D supplementation on subjective and objective neuropathic manifestations in patients. Patients who fulfilled the inclusion criteria were recruited by independent clinicians from hospital diabetology clinics (fig. [1](#F1){ref-type="fig"}), and were then allocated to the 2 arms of the intervention, i.e. treatment and placebo, according to a sequential order generated by the hospital recording system.

Participants {#sec2_2}
------------

### Exclusion Criteria {#sec3_1}

These included: patients with a nondiabetic cause for neuropathy such as inflammatory rheumatic diseases, malignancy, hyperparathyroidism, alcoholism, renal or liver failure or vitamin B~12~ deficiency, patients takingdrugs that could cause peripheral neuropathy and patients with other causes for pain in the feet (peripheral arterial disease or infections).

### Inclusion Criteria {#sec3_2}

Adult patients with type 2 diabetes with DPN and vitamin D deficiency were eligible. In total, 228 type 2 diabetic patients were screened over a 1-year period from March 2012 to March 2013; 111 were excluded (fig. [1](#F1){ref-type="fig"}), and of the remaining 117, 59 were assigned to treatment and 58 to placebo. Two patients dropped out of the treatment group and 3 out of the placebo group. So, 57 patients in the treatment group and 55 in the placebo group with DPN and vitamin D deficiency completed the study, i.e. a total of 112 patients (48 males and 68 females) with an age range of 38--80 years. Type 2 diabetes was defined as a fasting plasma glucose level ≥7.0 mmol/l on at least two occasions or glycated hemoglobin (HbA1c) ≥6.5s% \[[@B8]\]. All patients attended regular follow-ups at the diabetic clinics of the Mubarak Al-Kabeer Hospital, Kuwait. A detailed history was recorded and a physical examination was conducted for all patients. Fasting blood glucose, renal, liver and lipid profiles and HbA1c were measured. The 25(OH)D level was also measured. Vitamin D deficiency was defined as a serum 25(OH)D concentration of \<50 nmol/ml. Written informed consent was obtained from all participants. The study protocol was approved by the Ethics Committees, Faculty of Medicine, Kuwait University, and the Ministry of Health, in accordance with the provisions for human research in the Declaration of Helsinki. The study subjects were drawn from the general population living in Kuwait, a geographic region which is sunny all the year round and where the majority of citizens have a dress code of covering up.

Study Outcomes {#sec2_3}
--------------

The primary outcome measures were the assessment of neuropathy using an NSS and an NDS. The NSS includes symptoms of neuropathy (the nature of pain, the location, the duration and the measures undertaken to alleviate symptoms). Generally, the NSS values ranged from 0 to 9, and a value \>5 was defined as neuropathy. The NDS includes ankle reflex, vibration, pinprick and temperature; its values ranged from 0 to 10, and a value \>6 was defined as neuropathy \[[@B3],[@B9],[@B10],[@B11]\].

The secondary outcome measure was the assessment of neuropathy by means of an NCS, performed on all patients using established, standard techniques \[[@B12],[@B13]\]. Measurements of latencies, amplitudes and conduction velocities were evaluated using previously established cut-off values, for the motor (peroneal, tibial, median and ulnar) and sensory (sural, median and ulnar) nerves \[[@B3],[@B14],[@B15]\].

The clinical assessment of peripheral neuropathy at baseline and after treatment was conducted for all patients by a single clinician (D.S.) who was blinded to the treatment choice. Thus in this study, type 2 diabetic patients who had an NSS \>5 and an NDS \>6, in addition to an abnormal NCS, were categorized as having DPN.

Serum Vitamin D Status {#sec2_4}
----------------------

Vitamin D status was determined at baseline and after treatment by measuring serum total 25(OH)D concentrations using radioimmunoassay kits (DiaSorin, Stillwater, Minn., USA) according to the manufacturer\'s instructions. A serum 25(OH)D concentration \<50 nmol/ml was defined as a vitamin D deficiency \[[@B16]\].

Intervention {#sec2_5}
------------

Concealed opaque envelopes were prepared for all study participants for allocation into the vitamin D treatment group or the placebo group. This was done under the direct control of a single investigator (H.M.). The treatment group received oral capsules of vitamin D~3~ (a capsule of cholecalciferol, 50,000 IU, Bronson, Lindon, Utah, USA) once weekly for 8 weeks \[[@B17]\]. The placebo group received starch capsules, also once weekly for 8 weeks. The study medications were visually indistinguishable from one another and were stored as advised by the manufacturers. The study participants and the outcome assessor were blinded to the treatment allocation once during the conclusion of the study. Primary and secondary outcome measures of all patients were reassessed after 8 weeks of intervention.

Clinical Evaluation {#sec2_6}
-------------------

The primary end point was the difference between baseline and after treatment in the NSS and NDS, and the secondary end point was changes in the electrophysiological study, i.e. the NCS, between baseline and after treatment. Compliance with supplementation was evaluated by repeating laboratory tests. Indirect measures to improve the adherence to interventions included educating the patients and scheduling appointments.

Statistical Analysis {#sec2_7}
--------------------

Data were analyzed using the Statistical Package for Social Sciences version 19.0 (SPSS Inc., Chicago, Ill., USA). Data are expressed as percentages or mean ± SD. Categorical variables were compared by χ^2^ test. The mean values of the continuous variables were compared using the independent-samples or paired-samples Student t test as appropriate. For skewed data, analysis was performed using the Mann-Whitney U test. The Spearman correlation coefficient was used to evaluate the correlation between the improvement in 25(OH)D and the NSS. Values of p \< 0.05 were considered to be statistically significant.

Results {#sec1_3}
=======

The demographic characteristics of the 2 groups at baseline are given in table [1](#T1){ref-type="table"}. There were no significant differences between the 2 groups regarding gender, age, duration of diabetes, body mass index, the complications of diabetes (retinopathy, coronary heart disease and stroke) or antidiabetic medications. The biochemical parameters of the treatment and placebo groups at baseline and posttreatment are given in table [2](#T2){ref-type="table"}. No significant difference was observed in glycemic control between the 2 groups, demonstrated by the HbA1c values (9.5 ± 2.1 vs. 8.9 ± 2.1s%, p \> 0.05). There were no differences in other metabolic parameters measured at baseline and after treatment between the two groups.

The baseline and follow-up NSS and NDS values and the vitamin D status before and after treatment for both study arms are shown in table [3](#T3){ref-type="table"}. Of the 57 patients in the treatment group, 38 (66.7s%) had normal 25(OH)D levels after the treatment period. The differences in the NSS, NDS and vitamin D status before and after treatment were used to compare the effect of vitamin D supplementation between the treatment and placebo groups. The reduction in the NSS values after treatment was significantly more in the treatment group than in the placebo group (−1.49 ± 1.37 vs. −0.20 ± 0.59, p \< 0.001), while no difference was noted for the NDS. Similarly, the improvement in the serum 25(OH)D concentration after treatment was extremely significant in the treatment group compared to the placebo group (32.8 ± 23.7 vs. 1.1 ± 3.6, p \< 0.0001). The Spearman correlation did not reveal any significant correlation between change in 25(OH)D and improvement in NSS (rho = −0.052, p = 0.702)

The NCS data on the latency, amplitude and conduction velocity for the motor and sensory nerves in both groups after the 8-week treatment period are given in table [4](#T4){ref-type="table"}. The baseline and follow-up results for the normal cut-off values for the peroneal and sural nerves including distal latencies, conduction velocities and amplitudes showed no statistical difference between the groups during the study period (table [5](#T5){ref-type="table"}). Changes in NCS in both groups after treatment were not significant. Only 1 patient had a normal NCS result (0.89s%) after 8 weeks and 3 patients in the treatment group (2.6s%) showed an improvement after the vitamin D treatment. No changes were observed in the NCS in the placebo group.

Discussion {#sec1_4}
==========

In this study, oral supplementation of a dose of cholecalciferol (a 50,000-IU capsule) once weekly for 8 weeks was associated with a significant improvement in the 25(OH)D concentration in the treatment group compared to placebo. The improvement in NSS was also significant in the treatment group compared to the placebo group. No improvement in NDS or NCS result was observed in either group after vitamin D supplementation.

These findings are consistent with our previous study \[[@B3]\] which reported vitamin D as an independent risk factor in peripheral neuropathy in patients with type 2 diabetes. This study has thus established that oral vitamin D supplementation corrects vitamin D deficiency, which leads to an improvement in the symptoms of neuropathy.

The main symptom improvement observed was in the sensation of neuropathic pain, especially burning/hyperesthesia. However, it is not clear whether this was because of an elevation of pain threshold or due to an improvement in the function of the affected nerves, or both \[[@B7],[@B18]\]. Vitamin D is a potent inducer of neurotrophins and neurotransmitters; the biological effect of vitamin D on the nervous system includes the biosynthesis of enzymes involved in neurotransmitter synthesis as well as substances involved in brain detoxification pathways. The addition of vitamin D potentiates the nerve growth factor (NGF), a protein required for the development and maintenance of several populations of neurons in the peripheral nervous system \[[@B19]\]. In animal studies, it has been shown that the addition of vitamin D~3~ analogs potentiates the reversal of the neurotrophic deficits of diabetes \[[@B20],[@B21]\]. However, the mechanisms to explain the observed symptomatic improvement in humans are yet to be elucidated. It has been reported that vitamin D analogs are also effective in inducing NGF in human cell lines \[[@B22],[@B23]\]. In the skin, epidermal keratinocytes are the primary source of NGF and decreased NGF in patients with diabetic polyneuropathy correlates with neuropathic indicators of sensory and autonomic nerve function \[[@B23]\].

No significant changes were observed in NDS (ankle reflex, pinprick or vibration), probably due to an inadequate dose or duration of supplementation or both. The majority of our patients did not show an improvement in NCS with treatment. This could also be due to the underlying pathophysiology of peripheral neuropathy in diabetes, since the duration of diabetes in our patients was prolonged (years) and the pathophysiology of neuropathy could be mainly axonal; it takes longer than 8 weeks for nerves to be regenerated or to correct the effects of an absence of vitamin D.

Only 1 (0.89s%) patient had a normal NCS result after 8 weeks and 3 (2.6s%) showed an improvement after treatment, observed in the motor conduction velocity of the peroneal and tibial nerves and the sensory conduction velocity in the sural nerves. The NCS was conducted by the same clinician using the same machine and standard techniques, so the likelihood of technical bias was reduced. Interestingly enough, in animal models of diabetes \[[@B21]\], no changes were observed in the motor or sensory conduction velocities after 8 weeks of treatment with a vitamin D~3~ derivative. It is, therefore, tempting to speculate that the human and animal experimental findings were comparable. The effects observed in this study were not biased by any changes in glycemic control, since no significant differences were noted between the treatment and placebo groups in HbA1c before or after treatment.

A randomized, placebo-controlled, double-blind study \[[@B5]\] that used a topical cream containing vitamin D~3~ in 34 type 1 and type 2 diabetic patients led to an improvement in symptoms and quality of life. In a study by Lee and Chen \[[@B6]\], 51 type 2 diabetic patients with neuropathic pain and vitamin D deficiency were treated with oral vitamin D~3~, and then reevaluated after 3 months. They showed an improvement on a visual analog scale. The most recent similar account was a case report by Bell \[[@B7]\], where oral vitamin D supplementation, even in a type 1 diabetic patient, led to a dramatic improvement in neuropathic symptoms.

The main limitation of this study was the nonrandomization of the selection of patients. However, there were also several strengths: it was a prospective, placebo-controlled, double-blind study with a large sample. Two previously validated neuropathic scores, namely the NSS and NDS as primary outcome measures and an NCS as a secondary outcome measure, were used.

Conclusions {#sec1_5}
===========

This study showed that short-term oral supplementation of vitamin D to correct a deficiency improved the symptoms of peripheral neuropathy in patients with type 2 diabetes. We recommend conducting randomized, controlled trials in order to explore, prospectively, the issues of proper dosing as well as the route and duration of treatment, to confirm the efficacy and clinical benefits of vitamin D supplementation on DPN.
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###### 

Demographic characteristics of type 2 diabetic subjects in the treatment and placebo groups at baseline

  Characteristics          Treatment group (n = 57)   Placebo group (n = 55)   p value
  ------------------------ -------------------------- ------------------------ ---------
  Gender                                                                       0.190
   Male                    21 (36.8)                  27 (49.1)                
   Female                  36 (63.2)                  28 (50.9)                
  Mean age ± SD, years     61.8 ± 8.1                 59.8 ± 9.6               0.229
   Range                   45 -- 80                   38 -- 78                 
  Duration of diabetes                                                         0.116
   \>10 years              44 (77.2)                  35 (63.6)                
   \<10 years              13 (22.8)                  20 (36.4)                
  Body mass index                                                              0.247
   \<25                    8 (14.0)                   4 (7.3)                  
   \>25                    49 (86.0)                  51 (92.7)                
  Retinopathy                                                                  0.235
   Positive                20 (46.5)                  12 (33.3)                
  Coronary heart disease                                                       0.389
   Positive                16 (32.7)                  10 (24.4)                
  Stroke                                                                       0.694
   Positive                2 (3.6)                    1 (2.3)                  
  Treatment                                                                    0.507
   OHA only                20 (35.1)                  25 (45.5)                
   Insulin only            6 (10.5)                   4 (7.3)                  
   Insulin s+ OHA          31 (54.4)                  26 (47.3)                

Values denote n (s%), unless otherwise indicated. OHA = Oral hypoglycemic agent.

###### 

Metabolic parameters of the treatment and placebo groups at baseline (before treatment) and after treatment

  Parameters                  Treatment group (n = 57)   Placebo group (n = 55)   p value
  --------------------------- -------------------------- ------------------------ ---------
  HbA1c, s%                                                                       
   Before                     9.2 ± 2.2                  8.6 ± 2.1                0.840
   After                      9.5 ± 2.1                  8.9 ± 2.1                0.122
  Creatinine, µmol/l                                                              
   Before                     68.6 ± 25.2                70.7 ± 23.8              0.651
   After                      69.3 ± 27.7                70.0 ± 24.6              0.858
  Total cholesterol, mmol/l                                                       
   Before 4.5 ± 1.1           4.9 ± 0.9                  0.600                    
   After                      4.6 ± 1.2                  4.7 ± 1.1                0.558
  Triglycerides, mmol/l                                                           
   Before                     1.6 ± 0.9                  1.9 ± 0.9                0.080
   After                      1.7 ± 0.9                  1.9 ± 0.9                0.140
  HDL-C, mmol/l                                                                   
   Before                     1.1 ± 0.1                  1.1 ± 0.5                0.090
   After                      1.0 ± 0.3                  1.0 ± 0.3                0.713
  LDL-C, mmol/l                                                                   
   Before                     2.6 ± 0.9                  2.8 ± 1.9                0.475
   After                      2.7 ± 0.9                  2.7 ± 1.0                0.816
  Serum calcium, mmol/l                                                           
   Before                     2.4 ± 0.1                  2.5 ± 0.2                0.212
   After                      2.3 ± 0.09                 2.4 ± 0.1                0.223
  Serum albumin, g/l                                                              
   Before                     37.4 ± 7.1                 38.4 ± 7.9               0.482
   After                      37.8 ± 6.0                 39.2 ± 6.2               0.226
  AST, IU/l                                                                       
   Before                     22.7 ± 8.6                 25.5 ± 10.8              0.131
   After                      23.8 ± 10.9                23.9 ± 7.8               0.954
  ALT, IU/l                                                                       
   Before                     24.3 ± 12.4                29.0 ± 14.6              0.068
   After                      23.2 ± 12.3                26.8 ± 11.9              0.137
  ALP, IU/l                                                                       
   Before                     83.5 ± 25.1                74.9 ± 23.7              0.065
   After                      79.0 ± 27.4                75.2 ± 28.4              0.490

Values represent mean ± SD. ALP = Alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; HDLC = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.

###### 

Baseline and follow-up values and comparison of differences in NSS, NDS and vitamin D status before and after treatment between the treatment and placebo groups

  Parameters        Before        After         Differences[^1^](#T3F1){ref-type="table-fn"}   p value
  ----------------- ------------- ------------- ---------------------------------------------- ----------
  NSS                                                                                          
   Treatment        5.92 ± 1.29   4.43 ± 1.58   −1.49 ± 1.37                                   \<0.001
   Placebo          5.50 ± 1.25   5.45 ± 1.20   −0.20 ± 0.59                                   
  NDS                                                                                          
   Treatment        8.4 ± 1.8     8.4 ± 1.8     −0.42 ± 1.59                                   0.094
   Placebo          7.8 ± 1.9     7.7 ± 1.8     −0.03 ± 0.2                                    
  25(OH)D, mmol/l                                                                              
   Treatment        25.3 ± 10.9   58.2 ± 23.8   32.8 ± 23.7                                    \<0.0001
   Placebo          29.2 ± 9.5    30.3 ± 8.9    1.1 ± 3.6                                      

Values represent mean ± SD. The Mann-Whitney U test was used.

The minus sign indicates that the values decreased after treatment.

###### 

NCS data including cut-off values for the treatment group and the placebo group after treatment

                             Treatment group (n = 57)   Placebo group (n = 55)   Normal cut-off values   p value[^1^](#T4F1){ref-type="table-fn"}
  -------------------------- -------------------------- ------------------------ ----------------------- ------------------------------------------
  Distal latency, mV                                                                                     
   Median motor              4.5 ± 0.9                  5.4 ± 2.4                \<3.7                   0.434
   Median sensory            3.1 ± 0.4                  3.3 ± 0.7                \<2.9                   0.611
   Ulnar motor               2.6 ± 0.2                  2.7 ± 0.1                \<3.2                   0.555
   Ulnar sensory             2.7 ± 0.4                  2.3 ± 0.2                \<3.0                   0.323
   Peroneal motor            5.2 ± 1.0                  5.1 ± 1.0                \<5.6                   0.783
   Tibial motor              4.9 ± 0.6                  4.8 ± 0.6                \<5.6                   0.636
   Sural sensory             3.3 ± 0.2                  3.5 ± 0.3                \<3.5                   0.692
  Conduction velocity, m/s                                                                               
   Median motor              44.0 ± 4.9                 46.5 ± 9.1               \>50                    0.214
   Median sensory            48.0 ± 6.3                 44.0 ± 12.7              \>50                    0.612
   Ulnar motor               52.0 ± 4.3                 50.0 ± 1.4               \>50                    0.784
   Ulnar sensory             52.8 ± 3.4                 51.0 ± 1.4               \>50                    0.522
   Peroneal motor            37.0 ± 15.6                42.7 ± 11.5              \>40                    0.175
   Tibial motor              44.0 ± 4.8                 44.0 ± 9.6               \>40                    0.220
   Sural sensory             41.4 ± 5.0                 39.2 ± 3.1               \>40                    0.310
  Motor amplitude, mV                                                                                    
   Median                    5.9 ± 2.2                  5.5 ± 4.0                \>5                     0.458
   Ulnar                     8.5 ± 1.7                  8.4 ± 0.7                \>5                     0.958
   Peroneal                  2.2 ± 2.3                  2.8 ± 1.9                \>1.5                   0.325
   Tibial                    5.9 ± 4.1                  6.2 ± 3.4                \>5                     0.752
  Sensory amplitude, µV                                                                                  
   Median                    17.2 ± 3.7                 15.0 ± 7.0               \>15                    0.618
   Ulnar                     17.6 ± 4.3                 20.5 ± 0.1               \>15                    0.414
   Sural                     5.9 ± 2.3                  6.3 ±.2.4                \>9                     0.714

Values represent mean ± SD.

Independent-samples t test.

###### 

Comparison of NCS data on the peroneal and sural nerves before and after treatment in the treatment and the placebo group

                               Before treatment   After treatment   Normal cut-off values   p value[^1^](#T5F1){ref-type="table-fn"}
  ---------------------------- ------------------ ----------------- ----------------------- ------------------------------------------
  *Distal latency, mV*                                                                      
  Peroneal motor                                                    \<5.6                   
   Treatment                   5.3 ± 0.8          5.2 ± 1.0                                 0.373
   Placebo                     4.9 ± 1.1          5.1 ± 1.0                                 0.060
  Sural sensory                                                     \<3.5                   
   Treatment                   3.4 ± 0.4          3.3 ± 0.2                                 0.499
   Placebo                     3.4 ± 0.3          3.5 ± 0.3                                 0.064
  *Conduction velocity, m/s*                                                                
  Peroneal motor                                                    \>40                    
   Treatment                   36.1 ± 15.0        37.0 ± 15.6                               0.372
   Placebo                     43.2 ± 11.7        42.7 ± 11.5                               0.244
  Sural sensory                                                     \>40                    
   Treatment                   41.0 ± 5.2         41.4 ± 5.0                                0.741
   Placebo                     39.1 ± 3.2         39.2 ± 3.1                                0.866
  *Motor amplitude, mV*                                                                     
  Peroneal motor                                                    \>1.5                   
   Treatment                   2.0 ± 1.1          2.2 ±2.3                                  0.496
   Placebo                     2.9 ± 2.3          2.8 ±1.9                                  0.071
  *Sensory amplitude, µV*                                                                   
  Sural sensory                                                     \>9                     
   Treatment                   6.3 ± 2.6          5.9 ± 2.3                                 0.526
   Placebo                     6.4 ± 2.2          6.3 ± 2.4                                 0.354

Values represent mean ± SD.

Paired-samples t test.
